Zoetis Inc. (NYSE:ZTS) Shares Sold by Congress Park Capital LLC

Congress Park Capital LLC reduced its stake in Zoetis Inc. (NYSE:ZTS) by 8.7% during the 1st quarter, Holdings Channel reports. The fund owned 9,215 shares of the company’s stock after selling 875 shares during the period. Congress Park Capital LLC’s holdings in Zoetis were worth $1,559,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Blue Bell Private Wealth Management LLC lifted its position in Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock worth $25,000 after buying an additional 89 shares during the period. Independence Bank of Kentucky lifted its position in Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock worth $33,000 after buying an additional 130 shares during the period. Private Wealth Management Group LLC purchased a new position in Zoetis during the fourth quarter worth about $33,000. Ramirez Asset Management Inc. purchased a new position in Zoetis during the third quarter worth about $35,000. Finally, Gladius Capital Management LP purchased a new position in shares of Zoetis in the 4th quarter worth about $40,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now directly owns 14,800 shares in the company, valued at approximately $2,237,316. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the company. HSBC cut their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, May 8th. Piper Sandler restated an “overweight” rating and set a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. The Goldman Sachs Group lowered their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research note on Monday, May 6th. Stifel Nicolaus reduced their target price on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. Finally, Barclays cut their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $211.75.

Zoetis Stock Down 0.5 %

Shares of NYSE:ZTS traded down $0.92 on Friday, reaching $175.54. The company had a trading volume of 979,057 shares, compared to its average volume of 2,944,148. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $201.92. The stock has a 50-day moving average price of $167.68 and a 200 day moving average price of $178.94. The stock has a market capitalization of $80.10 billion, a P/E ratio of 33.81, a P/E/G ratio of 2.65 and a beta of 0.88. The company has a quick ratio of 1.94, a current ratio of 3.33 and a debt-to-equity ratio of 1.30.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.04. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm had revenue of $2.19 billion for the quarter, compared to analyst estimates of $2.14 billion. During the same period in the previous year, the company posted $1.31 earnings per share. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. On average, equities analysts expect that Zoetis Inc. will post 5.76 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Investors of record on Thursday, July 18th will be issued a dividend of $0.432 per share. The ex-dividend date is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a yield of 0.98%. Zoetis’s dividend payout ratio is 33.33%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.